FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1998210957> ?p ?o ?g. }

• W1998210957 endingPage "593" @default.
• W1998210957 startingPage "584" @default.
• W1998210957 abstract "Graft-versus-host disease (GVHD) is a cause of serious morbidity and mortality in >50% of recipients of unrelated hematopoietic stem cell transplantation (HSCT). We performed a trial using Campath 1 H pre- and post-HSCT in an attempt to decrease the incidence of GVHD without increasing the risk of infection or relapse. Patients were retrospectively compared to a population of patients who received antithymocyte globulin (ATG) pre- and post-HSCT. Twenty-seven patients were evaluated for this study. Fourteen patients received Campath 1H and 13 patients received ATG. Demographics of patients who received Campath 1H consisted of 9 males and 5 females, with a median age of 13 years (3-17.8 years). Thirteen patients received unrelated bone marrow and 1 patient received unrelated PBSC. Demographics of patients receiving ATG consisted of 9 males, 4 females with a median age of 7.4 years (21 months-19 years). Twelve patients received unrelated bone marrow and 1 patient received unrelated PBSC. Diagnoses were similar between the 2 groups. Patients who received Campath1H received a total dose of 52 mg/m(2) pre-HSCT and 20 mg/m(2) post-HSCT. Patients who received ATG received a total dose of 60 mg/kg pre-HSCT and 100 mg/kg post-HSCT. GVHD prophylaxis and supportive care measures were similar in both groups, including aggressive antimicrobial therapy. There was a significant difference in the incidence of severe (grade III and grade IV) GVHD between the 2 groups (Campath [0 of 14] versus ATG [6 of 13], P = .006). Among the patients who were transplanted for leukemia, there was no significant difference between the 2 groups in terms of relapse (Campath [2 of 14] versus ATG [4 of 9], P = 0.16). The 100-day survival between the 2 groups was not significantly different. Patients receiving Campath 1H had the presence of CD3(+) T cells (>30 cells/mL) in their peripheral blood later than in those who received ATG (64.5 days [Campath 1H] versus 27days [ATG], P = .001). The median time to the development of a normal PHA response occurred later in the Campath 1H arm (283 days[(Campath 1H] versus 88 days [ATG], P = .0001). The median time to an antigen specific response also occurred later in those receiving Campath 1H (365 days [Campath 1H] versus 150 days [ATG], P = .004). There was no significant difference between the 2 groups in terms of fungal or viral infections. Campath 1H is effective in decreasing the incidence of GVHD without increasing the risk of relapse. Although there is a significant delay in immune reconstitution, there was no increase in infectious complications or relapse in recipients of Campath 1H. Further studies are warranted to assess if a lack of difference in infection rates are still demonstrated in larger cohorts." @default.
• W1998210957 created "2016-06-24" @default.
• W1998210957 creator A5009145909 @default.
• W1998210957 creator A5019711287 @default.
• W1998210957 creator A5028130799 @default.
• W1998210957 creator A5030067164 @default.
• W1998210957 creator A5045306382 @default.
• W1998210957 creator A5046180673 @default.
• W1998210957 creator A5048686922 @default.
• W1998210957 creator A5050109992 @default.
• W1998210957 creator A5067009658 @default.
• W1998210957 date "2007-05-01" @default.
• W1998210957 modified "2023-09-28" @default.
• W1998210957 title "The Effects of Campath 1H upon Graft-Versus-Host Disease, Infection, Relapse, and Immune Reconstitution in Recipients of Pediatric Unrelated Transplants" @default.
• W1998210957 cites W1500757144 @default.
• W1998210957 cites W1547120987 @default.
• W1998210957 cites W1969788551 @default.
• W1998210957 cites W1984381597 @default.
• W1998210957 cites W1991455938 @default.
• W1998210957 cites W1993700655 @default.
• W1998210957 cites W1997989186 @default.
• W1998210957 cites W2053278212 @default.
• W1998210957 cites W2063156897 @default.
• W1998210957 cites W2076792352 @default.
• W1998210957 cites W2080813462 @default.
• W1998210957 cites W2107412758 @default.
• W1998210957 cites W2112095092 @default.
• W1998210957 cites W2135689851 @default.
• W1998210957 cites W2153392133 @default.
• W1998210957 cites W2157147843 @default.
• W1998210957 cites W2159599409 @default.
• W1998210957 cites W2170433336 @default.
• W1998210957 cites W2325413481 @default.
• W1998210957 cites W4236572065 @default.
• W1998210957 cites W78022547 @default.
• W1998210957 cites W83807906 @default.
• W1998210957 doi "https://doi.org/10.1016/j.bbmt.2007.01.076" @default.
• W1998210957 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17448918" @default.
• W1998210957 hasPublicationYear "2007" @default.
• W1998210957 type Work @default.
• W1998210957 sameAs 1998210957 @default.
• W1998210957 citedByCount "52" @default.
• W1998210957 countsByYear W19982109572012 @default.
• W1998210957 countsByYear W19982109572013 @default.
• W1998210957 countsByYear W19982109572014 @default.
• W1998210957 countsByYear W19982109572015 @default.
• W1998210957 countsByYear W19982109572017 @default.
• W1998210957 countsByYear W19982109572018 @default.
• W1998210957 countsByYear W19982109572019 @default.
• W1998210957 countsByYear W19982109572020 @default.
• W1998210957 countsByYear W19982109572021 @default.
• W1998210957 countsByYear W19982109572022 @default.
• W1998210957 crossrefType "journal-article" @default.
• W1998210957 hasAuthorship W1998210957A5009145909 @default.
• W1998210957 hasAuthorship W1998210957A5019711287 @default.
• W1998210957 hasAuthorship W1998210957A5028130799 @default.
• W1998210957 hasAuthorship W1998210957A5030067164 @default.
• W1998210957 hasAuthorship W1998210957A5045306382 @default.
• W1998210957 hasAuthorship W1998210957A5046180673 @default.
• W1998210957 hasAuthorship W1998210957A5048686922 @default.
• W1998210957 hasAuthorship W1998210957A5050109992 @default.
• W1998210957 hasAuthorship W1998210957A5067009658 @default.
• W1998210957 hasBestOaLocation W19982109571 @default.
• W1998210957 hasConcept C120665830 @default.
• W1998210957 hasConcept C121332964 @default.
• W1998210957 hasConcept C126322002 @default.
• W1998210957 hasConcept C141071460 @default.
• W1998210957 hasConcept C2777408962 @default.
• W1998210957 hasConcept C2779972918 @default.
• W1998210957 hasConcept C2908647359 @default.
• W1998210957 hasConcept C2911091166 @default.
• W1998210957 hasConcept C61511704 @default.
• W1998210957 hasConcept C71924100 @default.
• W1998210957 hasConcept C99454951 @default.
• W1998210957 hasConceptScore W1998210957C120665830 @default.
• W1998210957 hasConceptScore W1998210957C121332964 @default.
• W1998210957 hasConceptScore W1998210957C126322002 @default.
• W1998210957 hasConceptScore W1998210957C141071460 @default.
• W1998210957 hasConceptScore W1998210957C2777408962 @default.
• W1998210957 hasConceptScore W1998210957C2779972918 @default.
• W1998210957 hasConceptScore W1998210957C2908647359 @default.
• W1998210957 hasConceptScore W1998210957C2911091166 @default.
• W1998210957 hasConceptScore W1998210957C61511704 @default.
• W1998210957 hasConceptScore W1998210957C71924100 @default.
• W1998210957 hasConceptScore W1998210957C99454951 @default.
• W1998210957 hasIssue "5" @default.
• W1998210957 hasLocation W19982109571 @default.
• W1998210957 hasLocation W19982109572 @default.
• W1998210957 hasOpenAccess W1998210957 @default.
• W1998210957 hasPrimaryLocation W19982109571 @default.
• W1998210957 hasRelatedWork W1994968709 @default.
• W1998210957 hasRelatedWork W2047967234 @default.
• W1998210957 hasRelatedWork W2052860239 @default.
• W1998210957 hasRelatedWork W2166499099 @default.
• W1998210957 hasRelatedWork W2522420753 @default.
• W1998210957 hasRelatedWork W2559999242 @default.
• W1998210957 hasRelatedWork W2884628875 @default.
• W1998210957 hasRelatedWork W2911103373 @default.

• next